File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Mitotic checkpoint defects in human cancers and their implications to chemotherapy

TitleMitotic checkpoint defects in human cancers and their implications to chemotherapy
Authors
KeywordsCancer
Chemotherapy
Mitotic checkpoint
Issue Date2008
PublisherFrontiers in Bioscience.
Citation
Frontiers In Bioscience, 2008, v. 13 n. 6, p. 2103-2114 How to Cite?
AbstractThe mitotic checkpoint, also known as spindle assembly checkpoint, is to ensure accurate chromosome segregation by inducing mitotic arrest when errors occur in the spindle structure or in the alignment of the chromosomes on the spindle. Loss of mitotic checkpoint control is a common event in human cancer cells, which is thought to be responsible for chromosome instability frequently observed in cancer cells. Several reports have shown that cells with a defective mitotic checkpoint are more resistant to several types of anticancer drugs from microtubule disrupters to DNA damaging agents. In addition, inactivation of key mitotic checkpoint proteins such as BUB (budding uninhibited by benzimidazole) and MAD (mitotic arrest deficient) is influential in drug resistance in mitotic checkpoint defective cancer cells. The mitotic checkpoint has also been linked to DNA damage response and a defective mitotic checkpoint confers cancer cells resistance to certain DNA damaging anticancer drugs. This review presents recent evidence on mitotic checkpoint defects in human cancers and their association with resistance to anticancer drugs. In addition, the clinical importance and potential therapeutic implications of targeting the mitotic checkpoint to reverse drug resistance in cancer cells are also discussed.
Persistent Identifierhttp://hdl.handle.net/10722/67855
ISSN
2015 Impact Factor: 2.484
2015 SCImago Journal Rankings: 1.583
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorWang, Xen_HK
dc.contributor.authorHiu, WCen_HK
dc.contributor.authorChun, ACSen_HK
dc.contributor.authorJin, DYen_HK
dc.contributor.authorWong, YCen_HK
dc.date.accessioned2010-09-06T05:58:53Z-
dc.date.available2010-09-06T05:58:53Z-
dc.date.issued2008en_HK
dc.identifier.citationFrontiers In Bioscience, 2008, v. 13 n. 6, p. 2103-2114en_HK
dc.identifier.issn1093-9946en_HK
dc.identifier.urihttp://hdl.handle.net/10722/67855-
dc.description.abstractThe mitotic checkpoint, also known as spindle assembly checkpoint, is to ensure accurate chromosome segregation by inducing mitotic arrest when errors occur in the spindle structure or in the alignment of the chromosomes on the spindle. Loss of mitotic checkpoint control is a common event in human cancer cells, which is thought to be responsible for chromosome instability frequently observed in cancer cells. Several reports have shown that cells with a defective mitotic checkpoint are more resistant to several types of anticancer drugs from microtubule disrupters to DNA damaging agents. In addition, inactivation of key mitotic checkpoint proteins such as BUB (budding uninhibited by benzimidazole) and MAD (mitotic arrest deficient) is influential in drug resistance in mitotic checkpoint defective cancer cells. The mitotic checkpoint has also been linked to DNA damage response and a defective mitotic checkpoint confers cancer cells resistance to certain DNA damaging anticancer drugs. This review presents recent evidence on mitotic checkpoint defects in human cancers and their association with resistance to anticancer drugs. In addition, the clinical importance and potential therapeutic implications of targeting the mitotic checkpoint to reverse drug resistance in cancer cells are also discussed.en_HK
dc.languageengen_HK
dc.publisherFrontiers in Bioscience.en_HK
dc.relation.ispartofFrontiers in Bioscienceen_HK
dc.subjectCanceren_HK
dc.subjectChemotherapyen_HK
dc.subjectMitotic checkpointen_HK
dc.subject.meshAnimalsen_HK
dc.subject.meshAntineoplastic Agents - pharmacologyen_HK
dc.subject.meshCell Cycle - drug effectsen_HK
dc.subject.meshCell Cycle Proteins - chemistryen_HK
dc.subject.meshChromosome Segregationen_HK
dc.subject.meshDNA Damageen_HK
dc.subject.meshGene Expression Regulation, Neoplasticen_HK
dc.subject.meshHumansen_HK
dc.subject.meshMitosisen_HK
dc.subject.meshMitotic Spindle Apparatusen_HK
dc.subject.meshNeoplasms - drug therapy - metabolism - pathologyen_HK
dc.subject.meshSignal Transductionen_HK
dc.subject.meshTaxoids - pharmacologyen_HK
dc.titleMitotic checkpoint defects in human cancers and their implications to chemotherapyen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=1093-9946&volume=13&spage=2103&epage=2114&date=2008&atitle=Mitotic+checkpoint+defects+in+human+cancers+and+their+implications+to+chemotherapyen_HK
dc.identifier.emailJin, DY:dyjin@hkucc.hku.hken_HK
dc.identifier.emailWong, YC:ycwong@hkucc.hku.hken_HK
dc.identifier.authorityJin, DY=rp00452en_HK
dc.identifier.authorityWong, YC=rp00316en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.2741/2827en_HK
dc.identifier.pmid17981695-
dc.identifier.scopuseid_2-s2.0-38449089415en_HK
dc.identifier.hkuros140171en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-38449089415&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume13en_HK
dc.identifier.issue6en_HK
dc.identifier.spage2103en_HK
dc.identifier.epage2114en_HK
dc.identifier.isiWOS:000255775700171-
dc.publisher.placeUnited Statesen_HK
dc.identifier.scopusauthoridWang, X=7501854829en_HK
dc.identifier.scopusauthoridHiu, WC=6506527813en_HK
dc.identifier.scopusauthoridChun, ACS=7003650706en_HK
dc.identifier.scopusauthoridJin, DY=7201973614en_HK
dc.identifier.scopusauthoridWong, YC=7403041798en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats